• Perrigo recently reported past first-quarter 2026 results with adjusted earnings per share above estimates but revenue below expectations, citing softer consumer demand and inventory destocking, while it reaffirmed its full-year 2026 guidance.
• An interesting aspect is that management kept its outlook intact despite weaker sales trends and broadly lower analyst estimates, underscoring confidence in its current plan.
• We’ll now assess how Perrigo’s decision to reaffirm full-year guidance despite softer sales could influence the company’s broader investment narrative.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Perrigo Investment Narrative Recap

To own Perrigo, you generally have to believe in steady demand for affordable self care products and in management’s ability to stabilize earnings after recent losses. The latest quarter’s earnings beat but revenue miss highlights that softer consumer demand and inventory destocking remain the key short term overhang, while the reaffirmed 2026 sales outlook suggests the near term narrative around guidance has not materially changed, even as category softness stays the biggest risk.

The most relevant recent development here is Perrigo’s decision on May 6 to reaffirm its 2026 net sales guidance of a 5.5% to 1.5% decline, despite weaker first quarter revenue and a sizeable goodwill impairment. This sits directly against prior expectations that new OTC contracts and portfolio focus could support a firmer top line, and it keeps near term attention on whether cost savings and volume gains can offset category and pricing pressures in key businesses.

But while guidance has been reaffirmed, the risk that softer demand in core OTC categories could linger is something investors should be very aware of...

Perrigo's narrative projects $4.2 billion revenue and $73.4 million earnings by 2029. This requires flat yearly revenue growth and an earnings increase of about $1.9 billion from -$1.8 billion today.

Uncover how Perrigo's forecasts yield a $16.50 fair value, a 52% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were already assuming flat revenue near US$4.2 billion and only US$96.9 million in earnings by 2029, so this softer sales update could either reinforce their concerns about persistent demand weakness or prompt a rethink of just how pressured Perrigo’s future earnings power might be.

Explore 3 other fair value estimates on Perrigo - why the stock might be worth just $16.50!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Perrigo research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Perrigo research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Perrigo's overall financial health at a glance.

Seeking Other Investments?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 30 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.